Our Biotech Company Management & Board of Directors

Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific founders and expert in the field of drug resistance in cancer therapy. She is a biomedical scientist and biochemist by training (University of Fribourg and ETH Zurich) and holds a Ph.D. in Molecular and Translational Biomedicine from ETH Zurich. She led the team of scientist who discovered novel molecular mechanisms that can be exploited to prevent the development of resistance to cancer therapies.

Board of Directors

Isaac Kobrin, one of TOLREMO’s co-founders and Chairman of the Board, is an internationally trained internist with 23 years of experience in the pharmaceutical industry. As Global Group Leader of the Cardiovascular Development Group at Roche he was responsible for the worldwide clinical development of key compounds (from Phase 1 to marketing approval). In 1999, Isaac joined Actelion Pharmaceuticals as Senior Vice President, Head of Clinical Development, and member of Actelion's Executive Committee. He later became Chief Medical Officer and chairman of the Strategic and Portfolio Board of Actelion. 3 drugs were approved under his leadership and he was also directly involved in numerous regulatory interactions with the US-FDA and the European EMEA/CHMP.

Karl-Heinz Altmann co-founded TOLREMO and is Full Professor of Pharmaceutical Sciences and current Head of Department of Chemistry and Applied Biosciences at ETH Zurich. Before (re-)joining academia in 2003, he gained 13 years of experience as chemist and group leader at Ciba-Geigy and Novartis Pharma. In 2000, he was appointed Novartis Senior Chemistry Expert at Oncology Research of Novartis Pharma. Later he became acting Global Head of Chemistry of the Novartis Institutes for BioMedical Research (NIBR). At ETH Zurich his research group is centered on the chemical synthesis of pharmaceutically relevant natural products and their biological evaluation, with a particular focus on leads for anticancer and antituberculosis drug discovery. For his scientific achievements, Karl-Heinz was awarded the Paul Ehrlich Prize of the Société de Chimie Thérapeutique, France, in 2014.

Thomas Cerny is acting President of the Swiss Cancer Research Foundation, former President and current board member of the Swiss Cancer League, former President and current board member of Oncosuisse, and Board member of the Human Medicine Expert Committe (HMEC) of Swissmedic. He was Director of Oncology/Haematology at the Kantonsspital St. Gallen from 1998 to 2017 and Professor for Medical Oncology at the University of Berne from 1995 to 2017. He received several honors including the Robert Wenner Prize for cancer research.

Thomas Cerny was trained as medical doctor and oncologist at the University of Bern, Inselspital and the University of Manchester, Christie Hospital and Patterson Laboratories. His main research interests are in the field of new drug development as well as public health issues in oncology.

Erich Greiner founded Cedrus Therapeutics Inc. in May 2008 to develop novel therapeutic concepts and medicines. Erich Greiner serves as a strategic advisor and reviewer for several governmental, public and private institutions in the US and in Europe. These include several of the top European Venture Capitalist firms, the German Federal Ministry of Education and Research, and the Federal Ministry for Health. Before founding Cedrus, he held various senior positions within Evotec AG (SWX: EVT), in his last role as Chief Innovation Officer (CIO) and Member of the Management Team of Evotec.

Erich Greiner was trained in medicine and molecular biology at the Friedrich-Alexander University of Erlangen-Nürnberg and the Duke University Medical Center in Durham, NC, USA.

Andreas Wallnöfer joined BioMedPartners as General Partner in 2016. He is a senior executive leader with more than 20 years of experience in the pharmaceutical industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Leadership and Portfolio Committee. He also led the Roche Pharma Cardiovascular & Metabolism Disease Area and was involved in several successful product development programs. As Head of Clinical Research & Exploratory Development he was involved in the Due Diligence evaluations for in-licensing projects and product acquisitions.

Andreas has a PhD in Pharmacology from the University of Basel, Switzerland and trained as a fellow in Clinical Pharmacology at the University of Leiden, the Netherlands. He holds a Master of Technology Enterprise and an Executive MBA from IMD Lausanne, Switzerland.

Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific founders and expert in the field of drug resistance in cancer therapy. She is a biomedical scientist and biochemist by training (University of Fribourg and ETH Zurich) and holds a Ph.D. in Molecular and Translational Biomedicine from ETH Zurich. She led the team of scientist who discovered novel molecular mechanisms that can be exploited to prevent the development of resistance to cancer therapies.

Michael Sidler is an Observer of the Board at TOLREMO. In 2007, he co-founded Redalpine Venture Partners AG in Zurich and acts as General Partner for the currently existing Redalpine Capital Funds I – IV. Before Redalpine, Michael was responsible for corporate investments and M&A at Prionics AG, a Biotech company in Schlieren, Switzerland, where under his guidance several acquisitions were completed. From 1998 to 2003, Michael was with The Boston Consulting Group in Zurich and Toronto as a Consultant and Project Leader in several different industries and roles. He is a member of several organizations, juries and boards for the support of innovation, startups, and venture capital (Venturekick, Startup Finance, SECA).

Michael holds a PhD in Life Sciences from the University of Zurich.

In memoriam

Wilhelm Krek was one of TOLREMO’s co-founders and was Full Professor of Cell Biology at ETH Zurich since 2003. He was a world-leader in cancer cell signaling and had worked at the Friedrich Miescher Institute for Biomedical Research (FMI), Basel, and at the Dana Farber Cancer Institute/Harvard Medical School in Boston. He also co-founded the ETH Spin-off ProteoMedix AG, the Institute of Molecular Health Sciences, and the NEXUS Personalized Health Technologies Platform at ETH Zurich. For his work on cell signaling and disease mechanisms, he received several honors including the Robert Wenner Prize, the Friedrich Miescher Medal, the International Steiner Cancer Research Award and the Swiss Bridge Award. He was elected member of EMBO and the American Association for Cancer Research.

Willy was instrumental in laying the scientific foundation for the novel scientific principles that TOLRMEO is based on. Despite his untimely passing, his contagious enthusiasm, his passion for science, and his visionary thinking will remain at the heart of the company.